Saturday 17 October 2026
Export MDLN’s income statement to Excel — free account
Medline Inc.
MDLN Healthcare Medical Instruments & Supplies
Medline Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.4 billion, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 15.7% and free cash flow grew 3.42%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
35.96
0.61
−1.67%
Follow MDLN
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | 34.89 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | 45.50 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 43,000 | 45,000 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.59 | 0.63 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 23,231 | 25,507 | 28,432 | ||||
| Gross margin, % | — | — | — | — | — | — | — | 25.33 | 27.35 | 26.44 | |||||
| EBT | — | — | — | — | — | — | — | 264 | 1,246 | 1,248 | |||||
| EBT margin, % | — | — | — | — | — | — | — | 1.14 | 4.88 | 4.39 | |||||
| Net income | — | — | — | — | — | — | — | 234 | 1,200 | 1,157 | |||||
| Depreciation | — | — | — | — | — | — | — | 1,121 | 1,059 | 1,070 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 0.00 | 35.10 | ||||
| Earnings | — | — | — | — | — | — | — | — | — | 1.43 | |||||
| Cash flow | — | — | — | — | — | — | — | 0.00 | 0.00 | 2.15 | |||||
| Capex | — | — | — | — | — | — | — | 0.00 | 0.00 | (0.55) | |||||
| Free cash flow | — | — | — | — | — | — | — | 0.00 | 0.00 | 1.60 | |||||
| Book value | — | — | — | — | — | — | — | 0.00 | 0.00 | 23.81 | |||||
| Shares, m | — | — | — | — | — | — | — | — | — | 810 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.00 | 1.76 | |||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| EV/FCF | — | — | — | — | — | — | — | 4.66 | 4.66 | 13.20 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | 1,685 | 1,769 | 1,744 | ||||
| Capex | — | — | — | — | — | — | — | (275) | (354) | (447) | |||||
| Free cash flow | — | — | — | — | — | — | — | 1,410 | 1,415 | 1,297 | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 5,832 | 8,189 | ||||
| Total debt | — | — | — | — | — | — | — | — | 16,494 | 12,561 | |||||
| Net debt | — | — | — | — | — | — | — | — | 16,295 | 10,622 | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | 16,158 | 19,286 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | 6.67 | 3.11 | ||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 4.13 | 4.62 | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | 0.00 | 6.54 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Medline Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ISRG Intuitive Surgical, Inc. | $151.2B | 48.3× | 46.4× | +18.54% (above 0%: growing) | +25.54% (above 0%: growing) | +69.33% (above 0%: growing) | 67.78% | 33.60% | Compare |
| BDX Becton, Dickinson and Company | $52.8B | 57.8× | 37.7× | +5.44% (above 0%: growing) | −31.50% (below 0%: shrinking) | −31.57% (below 0%: shrinking) | 46.46% | 13.31% | Compare |
| MDLN Medline Inc. | $48.1B | — | — | +15.67% (above 0%: growing) | — | +3.42% (above 0%: growing) | 28.82% | 5.14% | |
| RMD ResMed Inc. | $34.1B | 22.8× | 16.6× | +8.58% (above 0%: growing) | +2.32% (above 0%: growing) | −21.31% (below 0%: shrinking) | 58.84% | 30.66% | Compare |
| ALC Alcon | $32.1B | 50.5× | 31.0× | +8.74% (above 0%: growing) | n/m | −0.54% (below 0%: shrinking) | 59.33% | 0.39% | Compare |
| WST West Pharmaceutical Services, Inc. | $27.0B | 48.7× | 37.3× | +13.80% (above 0%: growing) | +19.23% (above 0%: growing) | −20.71% (below 0%: shrinking) | 37.74% | 20.53% | Compare |
| SOLV Solventum Corporation | $15.0B | 10.4× | 39.0× | +2.22% (above 0%: growing) | +1.92% (above 0%: growing) | +144.07% (above 0%: growing) | 58.22% | 8.19% | Compare |
| BAX Baxter International Inc. | $13.3B | — (loss-making) | 44.7× | +5.34% (above 0%: growing) | +33.33% (above 0%: growing) | +119.48% (above 0%: growing) | 34.86% | 7.33% | Compare |
| RGEN Repligen Corporation | $11.7B | 234× | 112× | +11.93% (above 0%: growing) | −65.38% (below 0%: shrinking) | +27.10% (above 0%: growing) | 53.91% | 6.85% | Compare |
| Median of peers | $29.5B | 48.7× | 38.4× | +8.66% | +2.32% | +13.28% | 56.07% | 10.75% |
Medline Inc. (MDLN) key facts
- Strength: Medline Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.4 billion, up 11.5% from fiscal 2024.
- Medline Inc. (MDLN) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, MDLN traded at $35.96, a market capitalization of $48.1 billion.
- Return on equity was 6.54% and debt-to-equity 0.66.
- Its Altman Z-score is 2.25 (grey zone) for fiscal 2025.